From: FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma
Mean or number | Range or percentage | |
---|---|---|
Age at diagnosis (years) | 57 ± 11.85 | 16–87 |
Menopause status | ||
Pre-menopause | 33 | 26% |
Post-menopause | 94 | 74% |
Family history of cancer | ||
Yes | 7 | 5.5% |
No | 120 | 94.5% |
Preoperative CA125 level (IU/ml) | 1254.51 ± 2579.66 | 9.53–17,980 |
FIGO stage | ||
Stage I | 35 | 27.6% |
Stage II | 9 | 7.1% |
Stage III | 69 | 54.3% |
Stage IV | 14 | 11.0% |
Pathological pattern | ||
Serous | 90 | 70.9% |
Mucinous | 7 | 5.5% |
Clear cell | 21 | 16.5% |
Endometrioid | 9 | 7.1% |
Lymphatic metastasis | ||
Yes | 47 | 37.0% |
No | 80 | 63.0% |
Current status | ||
NED | 65 | 51.2% |
AWD | 19 | 15.0% |
DOD | 43 | 33.9% |
PFS (months) | 32.598 ± 23.0 | 4–109 |
OS (months) | 40.448 ± 24.5 | 4–109 |